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Myocardial Injury After
Transcatheter Aortic Valve Replacement*
William F. Fearon, MD, Alan C. Yeung, MDE very cardiac intervention is fraught with thepotential complication of myocardial injuryor infarction. The prognostic importance of
myocardial injury related to percutaneous coronary
intervention and coronary artery bypass grafting has
been well documented (1,2). After valvular heart sur-
gery, myocardial injury is common and is associated
with adverse outcomes (3). With the advent of trans-
catheter aortic valve replacement (TAVR), it is impor-
tant to understand the incidence, predictors, and
degrees of myocardial injury that can occur and their
relationships to outcomes.SEE PAGE 2075In this issue of the Journal, Ribeiro et al. (4) examined
data from a large registry to determine the incidence,
predictors, and degree of myocardial injury at the time
of TAVR and to assess the clinical impact of this
myocardial injury. Included in this study were 1,131
patients undergoing TAVR using either the balloon-
expandable valve system (58%) (Sapien, Edwards Life-
sciences, Irvine, California) or the self-expanding
system (42%) (Corevalve, Medtronic, Dublin, Ireland),
primarily the Medtronic system at 1 of 13 centers
participating in Canada, Brazil, Spain, or Switzerland.
The majority of these patients (73%) received the valve
from the transfemoral approach (TF-TAVR), whereas
most of the remainder (20%) received the valve from the
transapical approach (TA-TAVR).
Overall, two-thirds of patients had evidence
of myocardial injury at the time of TAVR, based on*Editorials published in the Journal of the American College of Cardiology
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Edwards Lifesciences, and Boston Scientiﬁc.a median 1.6-fold elevation of creatine kinase-
myocardial band (CK-MB). Of note, essentially all
TA-TAVR patients (97%) had elevation in CK-MB,
whereas approximately one-half of the non-TA-TAVR
patients did; in addition, the degree of CK-MB eleva-
tion was signiﬁcantly higher in the TA-TAVR cohort
(median peak value: 2.2-fold vs. 1.2-fold elevation;
p < 0.001). On multivariate analysis, TA-TAVR, early
TAVR experience, and procedural complications
were independent predictors of elevation of CK-MB.
When just evaluating patients receiving non-TA-
TAVR, use of a self-expanding valve, as compared to a
balloon expandable one, was an independent predic-
tor of an elevation in CK-MB, as were early TAVR
experience and procedural complications.
Overall, there was a signiﬁcant correlation between
elevations in CK-MB and change in left ventricular
ejection fraction, with those patients whose ejection
fraction did not change or declined having higher
levels of CK-MB. On multivariate analysis, an eleva-
tion in CK-MB was an independent predictor of
30-day mortality and of late mortality. In particular,
patients with >5-fold elevation in CK-MB had signif-
icantly higher mortality than those with lower ele-
vations or no elevation.
The strengths of this study include its large size,
multicenter nature, and the variety of approaches and
valve types that represent a “real-world” experience.
The prospective design with what appears to have
been careful data collection and an excellent follow-
up rate are additional strengths. A few limitations
are worth mentioning. Patients were not randomized
to treatment approach or valve type. We know from
previous studies that the TA cohorts have a higher
incidence of comorbidities. There was no indepen-
dent monitoring or clinical events committee adju-
dication of events, meaning there is always the
possibility of under- or over-reporting speciﬁc out-
comes. Echocardiographic data were incomplete,
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2090with only 63% of patients undergoing follow-up
echocardiograms at variable time points and without
a core laboratory evaluation. Overall, there was a 9%
mortality rate at 30 days (including the procedural
deaths), which is higher than most recent registries
and trials, perhaps related to inclusion of patients
since 2007, early in the TAVR experience. This point
in conjunction with the fact that currently available
valve systems were not evaluated in this study raises
the possibility that some or all of these ﬁndings are
not applicable to current technique.
This study is important because it demonstrates
clearly the high incidence of myocardial injury after
TAVR and its relationship with subsequent mortality.
Previous large randomized studies, like the PARTNER
(Placement of Aortic Transcatheter Valves) trials used
fairly strict criteria for deﬁning a myocardial infarc-
tion and therefore reported low rates after TAVR
(5,6). However, a recent substudy by the PARTNER
investigators found a high incidence of myocardial
injury when deﬁned by biomarker elevation alone
and documented an association with short- and long-
term mortality (7). Smaller studies by other groups
also have suggested a higher incidence of myocardial
injury and an association with adverse outcome, but
this is the ﬁrst large, multicenter, “real-world” study
to conﬁrm the ﬁndings (8,9). One could argue that
only a large degree of myocardial injury (>5-fold
elevation of CK-MB), which occurred in approxi-
mately 10% of patients is the most relevant clinically;
however, even 1- to 3-fold elevations of CK-MB seem
to predict an increase in early mortality, as was seen
in the PARTNER trial substudy as well (7). For these
reasons, it will be important to understand better the
cause of myocardial injury after TAVR and what can
be done to reduce its incidence.
Along these lines, 2 of the primary culprits for
myocardial injury in this study were using a TA
approach to TAVR and having less TAVR experience.
This is not surprising as previous studies have already
shown universal elevation of biomarkers after TA-
TAVR, with apical defects implicating the transapical
puncture and closure as the cause of the myocardial
injury (10). Although the rate of TA-TAVR will
continue to decline as the device proﬁle shrinks andexperience with alternative non-TA and non-TF
access routes increase, new techniques to reduce the
degree of myocardial injury after TA access to the left
ventricle will be critical for making procedures that do
require a TA approach safer, such as some trans-
catheter mitral procedures. The signiﬁcant learning
curve associated with TAVR and particularly with TA-
TAVR has been reported previously (11). The inde-
pendent association between TAVR experience and
myocardial injury is important because it highlights
the need for new TAVR sites to select carefully their
initial patients to minimize procedural complications.
An interesting ﬁnding in the non-TA-TAVR patients
in this study was the association between self-
expanding valve systems and higher incidence of
myocardial injury. A previous study found this same
relationship (12). Neither of these studies was ran-
domized, so it is possible that patients receiving self-
expanding valves were at higher risk for myocardial
injury. It is not obvious why a self-expanding valve
would be associated with increased myocardial injury.
Perhaps the longer procedure duration, potentially
involving more manipulation of the valve within
the annulus before deployment and more balloon
post-dilation after deployment results in greater stress
on the heart and greater opportunity for micro-
embolization of debris down the coronary arteries.
It is perhaps a bit discouraging that no other modi-
ﬁable predictors of myocardial injury after TAVR,
such as the presence of coronary disease, bore out as a
factor in this study.
Unanswered questions raised by this study include
the exactmechanismbywhichTAVR (in particular non-
TA-TAVR) results inmyocardial injury andwhether the
myocardial injury directly causes increased mortality
or occurs more commonly in certain patients who are
already at higher risk for mortality. Answering these
questions will be important, as it will determine if
prevention of myocardial injury is possible and
whether it is likely to improve outcomes.
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